| Line 14: |
Line 14: |
| | Adverse reactions to drugs including lack of expected efficacy occurring in the United Kingdom should be reported to the [[Drug Legislation| Veterinary Medicines Directorate (VMD)]] on their form MLA252A. Adverse events occurring in other European Union (EU) Member States, Norway, Iceland and Liechtenstein, should be reported to the relevant competent authority where the event occurred using the [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000176.jsp&mid=WC0b01ac058002ddcb/ EU reporting forms for veterinarians] which are available in each EU language on the [http://www.ema.europa.eu/ European Medicines Agency] website. | | Adverse reactions to drugs including lack of expected efficacy occurring in the United Kingdom should be reported to the [[Drug Legislation| Veterinary Medicines Directorate (VMD)]] on their form MLA252A. Adverse events occurring in other European Union (EU) Member States, Norway, Iceland and Liechtenstein, should be reported to the relevant competent authority where the event occurred using the [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000176.jsp&mid=WC0b01ac058002ddcb/ EU reporting forms for veterinarians] which are available in each EU language on the [http://www.ema.europa.eu/ European Medicines Agency] website. |
| | | | |
| − | The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other veterinary medicine-related problem is called veterinary pharmacovigilance. Further information on veterinary pharmacovigilance in the European Union, is available via the [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000190.jsp&mid=WC0b01ac058002d89c/ European Medicines Agency] and [http://eudravigilance.ema.europa.eu/veterinary/index.html EudraVigilance Veterinary] websites. | + | The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other veterinary medicine-related problem is called [[Pharmacovigilance|veterinary pharmacovigilance]]. Further information on [[Pharmacovigilance|veterinary pharmacovigilance]] in the European Union, is available via the [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000190.jsp&mid=WC0b01ac058002d89c/ European Medicines Agency] and [http://eudravigilance.ema.europa.eu/veterinary/index.html EudraVigilance Veterinary] websites. |
| | | | |
| − | ==Literature Search==
| + | {{Learning |
| − | [[File:CABI logo.jpg|left|90px]]
| + | |full text = [http://www.cabi.org/cabdirect/FullTextPDF/2005/20053195611.pdf '''Cutaneous adverse drug reactions.''' DeBoer, D. J.; Eastern States Veterinary Association, Gainesville, USA, Small animal and exotics. Proceedings of the North American Veterinary Conference, Volume 19, Orlando, Florida, USA, 8-12 January, 2005, 2005, pp 237-238] |
| − | | + | }} |
| − | | |
| − | Use these links to find recent scientific publications via CAB Abstracts (log in required unless accessing from a subscribing organisation).
| |
| − | <br><br><br>
| |
| − | [http://www.cabi.org/cabdirect/FullTextPDF/2005/20053195611.pdf '''Cutaneous adverse drug reactions.''' DeBoer, D. J.; Eastern States Veterinary Association, Gainesville, USA, Small animal and exotics. Proceedings of the North American Veterinary Conference, Volume 19, Orlando, Florida, USA, 8-12 January, 2005, 2005, pp 237-238 - '''Full Text Article'''] | |
| | | | |
| | | | |
| Line 28: |
Line 24: |
| | [[Category:Allergic Skin Diseases]] | | [[Category:Allergic Skin Diseases]] |
| | [[Category:To Do - Blood]][[Category:To Do - Clinical]] | | [[Category:To Do - Blood]][[Category:To Do - Clinical]] |
| | + | [[Category:Pharmacology]] |